Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine

Drug Metabolism and Disposition

Volumn 32, Issue 11, 2004, Pages 1213-1217

  Heydari, A ^a   Rowland Yeo, K ^b   Lennard, M S ^a   Ellis, S W ^a   Tucker, G T ^a,b   Rostami Hodjegan, A ^a,b,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b CERTARA UK LIMITED   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; ENZYME INHIBITOR; GLUTATHIONE; QUINIDINE;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DEMETHYLATION; DRUG BINDING; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER MICROSOME; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 6944246260     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001180     Document Type: Article

References (32)

1. Alfaro CL, Lam YW, Simpson J, and Ereshefsky L (1999) CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 19:155-163.
2. Ballard PG (1998) Tissue distribution and metabolism studies for a series of barbiturates. Ph.D. thesis, University of Manchester, Manchester, UK.
3. Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, and Witcher JW (2002) Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 42:1219-1227.
4. Bertelsen KM, Venkatakrishnan K, von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
5. Cole JC and Sumnall HR (2003) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98:35-58.
6. Crewe HK, Ellis SW, Lennard MS, and Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178.
7. Delaforge M, Jaouen M, and Bouille G (1999) Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D. Environ Toxicol Pharmacol 7:153-158.
8. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J, and Cami J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109.
9. Easton N, Fry J, O'Shea E, Watkins A, Kingston S, and Marsden CA (2003) Synthesis, in vitro formation and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy). Brain Res 987:144-154.
10. Ellis SW, Ching MS, Watson PF, Henderson CJ, Simula AP, Lennard MS, Tucker GT, and Woods HF (1992) Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast. Biochem Pharmacol 44:617-620.
11. Gilhooly TC and Daly AK (2002) CYP2D6 deficiency, a factor in ecstasy related deaths? Br J Clin Pharmacol 54:69-70.
12. Jacqz-Aigrain E, Funck-Brentano C, and Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
13. Jacqz-Aigrain E, Menard Y, Popon M, and Mathieu H (1989) Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. J Chromatogr 495:361-363.
14. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K, and Ishizaki T (1998) A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 286:1294-1300.
15. Kreth K, Kovar K, Schwab M, and Zanger UM (2000) Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59:1563-1571.
16. Laine K, De Bruyn S, Bjorklund H, Rouru J, Hanninen J, Scheinin H, and Anttila M (2004) Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol 59:893-898.
17. Laine K, Tybring G, Hartter S, Andersson K, Svensson JO, Widen J, and Bertilsson L (2001) Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 70:327-335.
18. Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, Tucker GT, and Cho AK (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 25:1059-1064.
19. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, and Goldman J (2002) Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline and paroxetine in healthy volunteers. J Clin Psychopharmacol 22:169-173.
20. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
21. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
22. O'Donohoe A, O'Flynn K, Shields K, Hawi Z, and Gill M (1998) MDMA toxicity. No evidence for a major influence of metabolic genotype at CYP2D6. Addict Biol 3:309-314.
23. Ortiz de Montellano PR (1995) Structure, mechanism and inhibition of cytochrome P450. Drug Metab Dispos 23:1181-1187.
24. Otton SV, Crewe HK, Lennard MS, Tucker GT, and Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247:242-247.
25. Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, and Sellers EM (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63:2111-2119.
26. Renwick AB, Watts PS, Edwards RJ, Barton PT, Guyonnet I, Price RJ, Tredger JM, Pelkonen O, Boobis AR, and Lake BG (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 28:1202-1209.
27. Schwab M, Seyringer E, Brauer RB, Hellinger A, and Griese EU (1999) Fatal MDMA intoxication. Lancet 353:593-594.
28. Segura M, Farre M, Pichini S, Peiro A, Roset PN, Ramirez A, Ortuno J, Pacific R, Zuccaro P, and Segura J (2004) Contribution of CYP2D6 to 3,4-methylenedioxymethamphetamine (MDMA) disposition in humans: use of paroxetine as a metabolic inhibitor probe. Clin Pharmacokinet, in press.
29. Silverman RB (1995) Mechanism-based enzyme inactivators, in: Enzyme Kinetics and Mechanism, Part D: Developments in Enzyme Dynamics (Purich DL ed), p 240, Academic Press, London.
30. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, and Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156.
31. Wu D, Otton SV, Inaba T, Kalow W, and Sellers EM (1997) Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 53:1605-1612.
32. Zanger UM, Raimundo S, and Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23-37.